Genetron Holdings, Ltd.
Genetron Holdings, Ltd. ("Genetron") is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. Genetron has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care.
Genetron is driven by its mission to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine. It offers its products and services through three business units: diagnosis and monitoring, early screening, and development services.
Genetron's comprehensive diagnostic services and products cover eight out of the top ten major cancers in China, capable of analyzing from focused gene panels to whole exome of approximately 21,000 genes. Depending on the nature of cancer and service types, it offers tissue biopsy, liquid biopsy, or both, providing great flexibility to patients and physicians to achieve the best clinical outcome.
On the frontier of early screening, Genetron has developed a leading technology platform and achieved breakthrough with its proprietary HCCscreen assays that enable early detection and intervention of liver cancer. Liver cancer is highly correlated with HBV infection, and China has approximately 73.9 million HBV carriers, representing significant market potential for precision early screening products.
Genetron collaborates with biopharmaceutical companies, hospitals and research institutions both in China and globally to serve their needs in genomics research and clinical development. Its products and services may be used by biopharmaceutical companies for a range of applications, including biomarker evaluation for molecularly targeted therapy and immuno-therapy, clinical trial enrollment, companion diagnostics development, and joint marketing post-drug approval. Genetron believes its collaboration with biopharmaceutical companies will also build evidence of clinical utility for its platform as an effective diagnostic for advanced cancer therapies.
Genetron believes advancing its services and products can expand the scope of precision oncology medicine to diagnosis, early screening, monitoring and continuous care, improve clinical outcomes, and reduce overall cancer treatment costs.
Location of Key Operations
Pricewaterhousecoopers Zhong Tian LLP
IPO (June 19, 2020)
6 Labs: Beijing, Shanghai, Hangzhou, Chongqing, Guangzhou, Maryland
Hoki Luk, Internal
September 27, 2021: Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline | Genetron Holdings Limited
September 16, 2021: Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021 | Genetron Holdings Limited
September 7, 2021: Genetron Added to FTSE Russell Global Equity Index Series | Genetron Holdings Limited (genetronhealth.com)
September 1, 2021: Genetron Health’s Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021 | Genetron Holdings Limited
August 24, 2021: Genetron Health Reports Second Quarter 2021 Unaudited Financial Results | Genetron Holdings Limited
August 23, 2021: Genetron Health Reaches Strategic Partnership with Yikon Genomics, Expanding S5 Platform’s Reach to Reproductive Health Field | Genetron Holdings Limited
August 23, 2021: Genetron Health to Host Calls Following Earnings and Participate in an Upcoming Investor Conference | Genetron Holdings Limited
July 13, 2021: Genetron Health Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test | Genetron Holdings Limited
July 1, 2021: Genetron Health Enters into Platform Partnership with World Economic Forum | Genetron Holdings Limited
June 4, 2021: Genetron Health Releases 16 New Research Results at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting | Genetron Holdings Limited
May 24, 2021: Genetron Health Reports First Quarter 2021 Unaudited Financial Results | Genetron Holdings Limited
May 20, 2021: Health Announces Strategic Partnership with JD Health to Create Innovative Solutions for Full-cycle Cancer Management | Genetron Holdings Limited
May 13, 2021: Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer | Genetron Holdings Limited
May 3, 2021: Genetron Health to Announce First Quarter 2021 Financial Results and Host Investor Call on May 24, 2021 | Genetron Holdings Limited
April 22, 2021: Genetron Health to Present at Upcoming Investor Conferences | Genetron Holdings Limited
April 13, 2021: Genetron Health Releases 22 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2021
April 1, 2021: Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science/AAAS Webinar
April 1, 2021: Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit
March 25, 2021: Genetron Health Reports Unaudited Fourth Quarter and Full Year 2020 Financial Results, and Provides 2021 Revenue Guidance
March 24, 20221: Genetron Health Releases New Data Results of HCCscreen™ for Liver Cancer Early Screening in China
March 17, 2021: Genetron Health to Participate at Credit Suisse Asian Investment Conference on Mar. 26th, 2021
March 15, 2021: Genetron Health to Present at Science/AAAS Webinar About Early Cancer Screening on March 31
March 4, 2021: Genetron Health to Announce Fourth Quarter and Full Year 2020 Unaudited Financial Results and Host Investor Call on March 25, 2021
February 9, 2021: Genetron Health’s Early Liver Cancer Screening Research Results Included in First Prevention and Treatment Guidelines for Patients in China
January 27, 2021: Genetron Health to Release Thirteen Research Findings at 21st World Conference on Lung Cancer
January 13, 2021: Genetron Health to Present at BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021
January 6, 2021: Genetron Health Announces Exclusive Strategic Partnership with Sino Biopharm Subsidiary for HCCscreen™ in China